# GLP-1 Receptor Agonists & Injectables

<table>
<thead>
<tr>
<th>Class/Main Action</th>
<th>Name</th>
<th>Dose Range</th>
<th>Considerations</th>
</tr>
</thead>
</table>
| GLP-1 Receptor Agonist (GLP-1 RA) “Incretin Mimetic”  
- Increases insulin release with food  
- Slows gastric emptying  
- Promotes satiety  
- Suppresses glucagon | exenatide (Byetta)  
exenatide XR† (Bydureon)  
liraglutide (Victoza)*†  
dulaglutide* (Trulicity)  
lixisenatide (Adlyxin)  
semaglutide* (Ozempic)  
(Rybelsus) Oral tablet | 5 and 10 mcg BID  
2 mg 1x a week  
Pen injector - Bydureon BCise  
0.6, 1.2 and 1.8 mg daily  
0.75, 1.5, 3.0 and 4.5 mg  
1x a week pen injector  
10 mcg 1x a day for 14 days  
20 mcg 1x day starting day 15  
0.5, 1.0 and 2.0 mg  
1x a week pen injector  
3, 7, and 14 mg daily in a.m.  
Take on empty stomach w/H2O sip | Side effects for all: Nausea, vomiting, weight loss, injection site reaction.  
Report signs of acute pancreatitis (severe abdominal pain, vomiting), stop med. Renally excreted.  
Black box warning: Thyroid C-cell tumor warning for exenatide XR, liрагlutide, dulaglutide, and semaglutide (avoid if family history of medullary thyroid tumor).  
*Significantly reduces risk of CV death, heart attack, and stroke.  
†Approved for pediatrics 10-17 yrs |

Lowers A1c 0.5 – 1.6%  
Weight loss of 1.6 to 6.0kg

| Amylin Mimetic  
- Slows gastric emptying  
- Supress glucagon | pramlintide (Symlin) | Type 1: 15 - 60 mcg;  
Type 2: 60 - 120 mcg immediately before major meals | For Type 1 or 2 on insulin.  
Severe hypoglycemic risk, decrease insulin dose when starting.  
Side effects: nausea, weight loss.  
Lowers A1c 0.5 – 1% |

DiabetesEd.net  © 4/2022
<table>
<thead>
<tr>
<th>Name</th>
<th>Combines</th>
<th>Considerations</th>
</tr>
</thead>
</table>
| IDegLira*          | Insulin degludec (IDeg or Tresiba) + Liraglutide (Victoza) GLP-1 Receptor Agonist (GLP-1 RA) | **Xultophy 100/3.6 pre-filled pen** = 100 units IDeg / 3.6 mg liraglutide per mL  
Once daily injection – Dose range 10 to 50 =  
10 – 50 units IDeg + 0.36 -1.8 mg liraglutide  
**Recommended starting dose:**  
• 16 IDegLira (= 16 units IDeg + 0.58 mg liraglutide)  
Titrate dose up or down by 2 units every 3-4 days to reach target.  
Supplied in package of five single-use 3mL pens.  
Once opened, good for 21 days. |
| iGlarLixi*         | Insulin glargine (Lantus) + Lixisenatide (Adlyxin) GLP-1 Receptor Agonist | **Soliqua 100/33 Solostar Pen** = 100 units glargine / 33 μg lixisenatide per mL  
Once daily injection an hour prior to first meal of day.  
Dose range 15 – 60 = 15-60 units glargine + 5 – 20μg lixisenatide  
**Recommended starting dose:**  
• 15 units if not meeting glucose target on 30 units basal insulin or GLP-1 RA  
• 30 units if not meeting glucose target on 30-60 units basal insulin or GLP-1 RA  
Titrate dose up or down by 2-4 units every week to reach target.  
Supplied in package of five single-use 3mL pens.  
Once opened, good for 14 days. |

*Discontinue basal insulin /GLP-1 RA therapy before starting. If dose missed, resume with next usual scheduled dose.*

Observe precautions of each component drug.